Latest Research

 

Huntington's disease

1. Panov AV, Lund S, Greenamyre JT. Ca2+-induced permeability transition in human lymphoblastoid cell mitochondria from normal and Huntington's disease individuals. Mol Cell Biochem. 2005 Jan;269(1-2):143-52.

2. Maciel EN, Kowaltowski AJ, Schwalm FD, Rodrigues JM, Souza DO, Vercesi AE, Wajner M, Castilho RF. Mitochondrial permeability transition in neuronal damage promoted by Ca2+ and respiratory chain complex II inhibition.
J Neurochem. 2004 Sep;90(5):1025-35.

3. Kristal BS, Stavrovskaya IG, Narayanan MV, Krasnikov BF, Brown AM, Beal MF, Friedlander RM. The mitochondrial permeability transition as a target for neuroprotection. J Bioenerg Biomembr. 2004 Aug;36(4):309-12.

4. Choo YS, Johnson GV, MacDonald M, Detloff PJ, Lesort M. Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release. Hum Mol Genet. 2004 Jul 15;13(14):1407-20. Epub 2004 May 26.

5. Ruan Q, Lesort M, MacDonald ME, Johnson GV. Striatal cells from mutant huntingtin knock-in mice are selectively vulnerable to mitochondrial complex II inhibitor-induced cell death through a non-apoptotic pathway. Hum Mol Genet. 2004 Apr 1;13(7):669-81. Epub 2004 Feb 12.

6. Zeron MM, Fernandes HB, Krebs C, Shehadeh J, Wellington CL, Leavitt BR, Baimbridge KG, Hayden MR, Raymond LA. Potentiation of NMDA receptor-mediated excitotoxicity linked with intrinsic apoptotic pathway in YAC transgenic mouse model of Huntington's disease. Mol Cell Neurosci. 2004 Mar;25(3):469-79.

7. Brustovetsky N, Brustovetsky T, Purl KJ, Capano M, Crompton M, Dubinsky JM. Increased susceptibility of striatal mitochondria to calcium-induced permeability transition. J Neurosci. 2003 Jun 15;23(12):4858-67.

8. Bachurin SO, Shevtsova EP, Kireeva EG, Oxenkrug GF, Sablin SO. Mitochondria as a target for neurotoxins and neuroprotective agents.
Ann N Y Acad Sci.
2003 May;993:334-44; discussion 345-9.

9. Hauser RA, Furtado S, Cimino CR, Delgado H, Eichler S, Schwartz S, Scott D, Nauert GM, Soety E, Sossi V, Holt DA, Sanberg PR, Stoessl AJ, Freeman TB.
Bilateral human fetal striatal transplantation in Huntington's disease. Neurology. 2002 Mar 12;58(5):687-95.

10. Rosser AE, Barker RA, Harrower T, Watts C, Farrington M, Ho AK, Burnstein RM, Menon DK, Gillard JH, Pickard J, Dunnett SB; NEST-UK. Unilateral transplantation of human primary fetal tissue in four patients with Huntington's disease: NEST-UK safety report ISRCTN no 36485475.
J Neurol Neurosurg Psychiatry.
2002 Dec;73(6):678-85.

11. Leventhal L, Sortwell CE, Hanbury R, Collier TJ, Kordower JH, Palfi S.
Cyclosporin A protects striatal neurons in vitro and in vivo from
3-nitropropionic acid toxicity.
J Comp Neurol. 2000 Oct 2;425(4):471-8.

12. Petersen A, Castilho RF, Hansson O, Wieloch T, Brundin P. Related
Oxidative stress, mitochondrial permeability transition and activation
of caspases in calcium ionophore A23187-induced death of cultured
striatal neurons.
Brain Res. 2000 Feb 28;857(1-2):20-9

13. Bachoud-Levi A, Bourdet C, Brugieres P, Nguyen JP, Grandmougin T, Haddad B, Jeny R, Bartolomeo P, Boisse MF, Barba GD, Degos JD, Ergis AM, Lefaucheur JP, Lisovoski F, Pailhous E, Remy P, Palfi S, Defer GL, Cesaro P, Hantraye P, Peschanski M. Safety and tolerability assessment of intrastriatal neural allografts in five patients with Huntington's disease. Exp Neurol. 2000 Jan;161(1):194-202.

14. Kopyov OV, Jacques S, Lieberman A, Duma CM, Eagle KS. Safety of intrastriatal neurotransplantation for Huntington's disease patients.
Exp Neurol.
1998 Jan;149(1):97-108.



© Maas Biolab All rights reserved